Ipsen Advances Elafibranor Into Phase III For Rare Liver Disease, Signaling Long-Term Upside Potential

Ipsen (GB:0MH6) announced an update on their ongoing clinical study.

The Phase III study “A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis” will test how well Ipsen’s elafibranor works and how safe it is in adults with primary sclerosing cholangitis, a rare and serious liver disease.

Elafibranor (IPN60190) is an oral tablet taken once a day, designed to reduce inflammation and scarring in the bile ducts and slow liver damage. The control group receives a matching placebo tablet, helping show whether any benefit comes from the drug itself rather than other factors.

The study is interventional and randomized, with patients assigned by chance to elafibranor or placebo in parallel groups. It is double blind, meaning neither patients nor doctors know who gets the active drug, and the main goal is to see if treatment can improve disease outcomes and safety versus placebo.

The trial plans to enroll about 350 adults with large duct primary sclerosing cholangitis and follow them for several years until enough disease events occur. This long duration should provide clearer evidence on whether elafibranor changes the course of the disease and supports potential future regulatory filings.

The study was first submitted on 28 January 2026, with the latest update filed on 27 February 2026, and it is currently listed as not yet recruiting. These early timelines show Ipsen is moving elafibranor into late-stage testing, though investors should note that meaningful data will likely not appear for several years.

For Ipsen (GB:0MH6), a successful outcome could open a high-value niche in a rare liver disease with limited treatment options, supporting revenue diversification and a premium for its pipeline. The update may lift long-term sentiment but near-term stock moves could stay modest given the long path to readout and competing efforts in cholestatic liver diseases from larger peers.

The elafibranor Phase III trial in primary sclerosing cholangitis is now formally posted and updated, and the study remains in the setup phase with full details available on the ClinicalTrials portal.

To learn more about GB:0MH6’s potential, visit the Ipsen drug pipeline page.